Bone Marrow Transplantation for Leukemia Following a New Busulfan and Cyclophosphamide Regimen

By Peter J. Tutschka, Edward A. Copelan, and John P. Klein

Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg were used as conditioning prior to allogeneic marrow transplantation in 50 adult patients with acute nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML). A standard risk group of 20 patients included those with acute leukemia in remission and CML in chronic phase. A high-risk group of 30 patients included individuals with refractory acute leukemia, acute leukemia in relapse, acute leukemia following preleukemia, and CML in accelerated and blastic phase. Complete remission and sustained complete engraftment were achieved in all evaluable patients. The duration of aplasia was remarkably short (median of 8 days), resulting in a low infection rate during the period of neutropenia, a reduced need for blood product support, and a short length of hospital stay. Three-year actuarial relapse-free survival in both standard-risk (88.9% ± 10.6%) and high-risk (50.5% ± 9.6%) groups compares favorably with that reported with total body irradiation (TBI) containing regimens.

ALLOGENEIC BONE MARROW transplantation following total body irradiation (TBI) and high-dose chemotherapy has provided encouraging therapeutic results in patients with hematologic malignancies. Apparent cure of ~50% of patients with acute nonlymphocytic leukemia (ANLL) in first remission and chronic myelogenous leukemia (CML) in chronic phase has been achieved; the success rate in acute lymphocytic leukemia (ALL) has been somewhat lower. Despite these results, several undesirable features of allogeneic marrow transplantation have limited its application. First, the usual side effects of the conditioning regimen together with prolonged periods of isolation often make transplantation a difficult ordeal for the patient. Second, common complications of marrow transplantation such as infections, graft-v-host disease (GVHD) and interstitial pneumonia (IP) may be lethal. Third, chronic complications such as chronic GVHD may result in a substandard quality of life despite a "successful" outcome. Last, relapse occurs in 10% to 40% of individuals transplanted under the best circumstances. These problems have understandably dampened the enthusiasm for this therapy.

The plateau in survival rates, observed over the recent past, may in large part reflect limitations of the traditional regimen of TBI and cyclophosphamide (Cy). Past attempts to replace TBI with chemotherapeutic agents have not met with an increased success rate. In a previous trial using busulfan with higher doses of Cy than are commonly used with TBI, a significantly lower relapse rate for ANLL in remission was achieved. A higher complication rate, however, caused a similar overall long-term disease-free survival as compared with TBI-containing regimens.

Because busulfan is the primary antileukemic agent in our regimen and because of the high complication rate in the previous trial, we used as a new conditioning regimen the same dose of busulfan but a lower dose of Cy. We describe the activity of this regimen in 50 consecutive adult patients transplanted with CML in chronic, accelerated, or blastic phase, and with ALL and ANLL in first or second remission, in relapse, or with refractory disease.

MATERIALS AND METHODS

All patients were entered on a study protocol that had been reviewed and approved by The Ohio State University Institutional Review Board.

Patient accrual. Fifty adult patients were consecutively entered into the study. Eligibility for the study required a diagnosis of ALL, ANLL, or CML, regardless of the remission status. All patients were ambulatory, had an HLA-identical sibling donor, and were aged >15 and ≤50 years. No other medical parameters were used as exclusion criteria. All diagnoses of leukemia were confirmed by examination of the bone marrow aspirate and biopsy. On admission, all patients had a bone marrow aspirate and bone marrow biopsy as well as a diagnostic lumbar puncture to assess the status of the leukemia. Presence of leukemic cells in the spinal fluid was not an exclusion criterion. All data are analyzed as of February 14, 1987. The patients were transplanted between February 13, 1984 and August 14, 1986; therefore, the observation period for these patients has been a minimum of 6 months and a maximum of 3 years.

Study groups. The study involved two groups of patients. A standard-risk group consisted of patients with acute leukemia in the first or second remission, or CML in the chronic phase. Twenty patients, 11 with ANLL in remission, 2 with ALL in remission, and 7 with CML in chronic phase were in this group. The high-risk group consisted of 30 patients with refractory acute leukemia, acute leukemia in relapse, or CML in accelerated or blastic phase. Refractory acute leukemia was defined as leukemia that failed to remit after two courses of conventional chemotherapy. Patients were considered to be in the accelerated phase of CML if they had ≥10% blasts in blood or marrow together with major perturbations of the leukocyte or platelet count unresponsive to chemotherapy with busulfan or hydroxyurea. They were considered to be in the blastic phase if they had ≥30% blasts in the blood or bone marrow. Among the patients in the high-risk group were two previously untreated patients in whom leukemia developed after a preleukemic syndrome (UPN 4 and UPN 17).

Twelve patients had ANLL, 4 had ALL, and 14 patients had CML in accelerated (n = 9), or blastic phase (n = 5).

Patient criteria. The median age of the recipients was 28 years (range 15 to 50 years). The median age of patients in the standard-risk group was 32 years (range 19 to 50 years), and the median age of...
the high-risk group 27 years (range 15 to 48 years). Thirty-four
patients were male and 16 patients were female. Thirty-four patients
were sex matched with their recipients (20 male to male, 9 female to
female transplants), and 16 patients were sex mismatched (6 male to
female and 10 female to male transplants). All patients were
identical for A, B, C, D/Dr locus with their allogeneic sibling donors.
When possible, genotypical analysis of the entire family was
performed. Seven patients had major blood group mismatches (6 male to
female transplants). The technical aspects of the procedure have
been described elsewhere. All donors tolerated the marrow aspiration
infusion.8

Bone marrow donors. All donors were required to give informed
consent prior to the procedure. All donations were carried out under
general anesthesia. The technical aspects of the procedure have been
described elsewhere.12 All donors tolerated the marrow aspiration
No significant complications of the marrow harvest procedure
occurred.

Preparative regimen. All patients were given methotrexate intrathoracally (10 mg/m² of body surface but not more than 12 mg
total) ~10 days prior to marrow transplantation. Three patients who
had central nervous system (CNS) leukemia at the beginning of the
transplant procedure were given four intrathoracic treatments of
methotrexate. Patients received busulfan orally at a dose of 1 mg/kg
of ideal body weight four times daily for 4 consecutive days for a
total dose of 16 mg/kg. Cyclophosphamide at a daily dose of 60
mg/kg of ideal body weight was administered intravenously (IV)
over a 1-hour period for 2 consecutive days. Bone marrow was
infused 2 days after the final dose of Cy.

Supportive therapy. On the day of hospitalization, all patients
were placed in ultraclean rooms equipped with HEPA-filtered
laminar air flow. Patients were treated in strict isolation. “Sterile
diet” with very low bacterial content was begun on day ~4 together
with oral Clotrimazole and oral Trimethoprim-Sulfamethoxazole.
Nonabsorbable antibacterial antibiotics were not used. All patients
had a double-lumen and a single-lumen right atrial catheter placed.
All patients received IV a commercial immunoglobulin preparation
(Sandoglobulin®) at a dose of 500 mg/kg every 2 weeks starting 1
week prior to transplant and ending at day 120 after transplant. The
first 31 patients did not receive immunoglobulin after that time, but
the 19 most recently transplanted patients were given the same
immunoglobulin preparation monthly until day 365. In an attempt
to prevent hemorrhagic viral gastroenteritis, the same immunoglobulin
preparation was given orally at a daily dose of 30 mg/kg in four
divided doses, starting at day 2 after transplant and maintained until
day 28. All blood products administered were derived from volunteer
donors who had a negative antibody titer against cytomegalovi-
rus.

Transplantation and evaluation of engraftment. The bone mar-
row was infused on day 8 through a right atrial catheter over 4 hours.
All patients tolerated the infusion well. The mean number of
nucleated marrow cells infused was 5.17 × 10⁸ ± 0.25 (± 1 SE)/kg
body weight of the recipient. This number was not corrected for
peripheral blood contamination. Engraftment was assessed indi-
rectly by peripheral blood counts and periodic marrow examinations.
An average of four routine marrow examinations were carried out
for each transplant course, the last one performed between 120 and
160 days (mean 147 days) after transplant. After that time, bone
marrow examinations were only carried out if hematologic and
cytogenetic parameters measured in the peripheral blood suggested
the occurrence of leukemia. Engraftment was measured directly by
cytogenetic markers, when available (sex or autosomal markers), RBC enzymes, and RBC antigens.

Determination of remission status posttransplantation. Pa-
patients were considered to be in complete remission (CR) after
transplantation for acute leukemia if they showed a completely
normal bone marrow and peripheral blood status together with the
absence of lymphohematopoietic cells of recipient origin by cyto-
genetic analysis.

Patients were considered to be in complete remission after trans-
plantation for CML if they showed a completely normal bone
marrow and peripheral blood status together with the absence of
lymphohematopoietic cells of recipient origin by cytogenetic analy-
sis. Patients who showed the presence of the Philadelphia chromo-
some prior to transplantation required the complete and persistent
disappearance of this chromosomal abnormality after transplanta-
tion to qualify for complete remission status.

GVHD. All patients received a combination of cyclosporine and
methyprednisolone to prevent GVHD. Cyclosporine started 1 day
prior to transplantation and was given as a continuous infusion of 5
mg/kg daily for 4 days. After that time, the dose of cyclosporine was
reduced to 3 mg/kg given IV over 6 hours daily until day 14. From
day 14 through day 35, the dose of cyclosporine was increased to
3.75 mg/kg given IV. Thereafter, cyclosporine was slowly tapered
until day 180, after which time it was discontinued. At discharge,
patients were given oral cyclosporine at a dose four times higher
than the IV dose. Methyprednisolone was started on day 7 at a dose of 0.5
mg/kg/day. On day 14, the dose was increased to 1 mg/kg/day and
was given until day 28. Then, until day 72, the methyprednisolone
was slowly tapered. All patients received prophylaxis for CNS
leukemia. Between day 70 and day 90 after bone marrow transplanta-
tion, four intrathoracic doses of 10 mg/m² each of methotrexate were
administered over 2 to 4 weeks.

Acute GVHD was assessed according to the grading system
described in the literature.10 Chronic GVHD was assessed using
descriptive criteria reported previously. Patients were assumed to
have chronic GVHD if they had the typical features of the disease14
and/or were given adrenal steroids after day 100. Patients with
chronic GVHD were divided into three groups according to severity,
grade 1 disease showing mild symptoms that resolve within 2
months, grade 2 showing mild symptoms that require 2 to 6 months
for resolution without sequelae, and grade 3 disease showing marked
symptoms that require >6 months of therapy.

Other common complications. Intestinal pneumonia was diag-
nosed when bilateral interstitial/alveolar infiltrates on chest x-ray
were associated with hypoxemia (PO2 on room air of ≤65 mm Hg).
Hemorrhagic gastroenteritis was diagnosed when diarrhea of
greater than 1,000 mL/day was present that was either bloody or
maroon and persisted for >3 days.

Statistical analysis. Estimates of survival probabilities and the
probability of being in remission were computed by using the
product-limit estimates of Kaplan and Meier.13 In estimating the
probability of being in remission, we treated those patients who died
free of leukemic disease as censored observations. A Cox's propor-
tional-hazards analysis was performed in each of the clinical vari-
ables displayed in Tables 1 and 2. Significance was judged using
the maximum likelihood chi-squared statistic.14

RESULTS

Early toxicity of the preparative regimen. The prepara-
tive regimen was generally very well tolerated. Mild nausea
and vomiting were noted during busulfan administration in
nine patients; the remaining patients all tolerated busulfan
well. On the days during which Cyclophosphamide was
administered, most patients experienced nausea and vomit-
ing requiring antiemetic therapy. None of the patients
developed severe oral mucositis, but most patients com-
plained of mild sore throat between 7 and 11 days after

From www.bloodjournal.org by guest on August 30, 2017. For personal use only.
transplant. Of the 50 patients, 32 had no evidence of hemorrhagic cystitis. Eight showed minimal microscopic hematuria, 5 patients showed macroscopic hematuria, and 5 patients showed severe hemorrhagic cystitis. Clinical symptoms of venoocclusive disease occurred in one patient (UPN 37), but resolved without any sequelae.

**Antileukemic effect.** With the exception of one patient who died on day 2 (UPN 38), all patients experienced a complete remission. This includes all patients with refractory disease and those in blast crisis of CML.

None of the patients transplanted in the standard-risk group to date have shown evidence of relapse. Among the 30 patients in the high-risk group, five patients all transplanted for acute leukemia experienced a clinical relapse (UPN 2, 7, 22, 35, and 52). Of the 14 patients transplanted for CML in accelerated or blastic phase, only one patient has shown evidence of relapse by cytogenetic analysis (UPN 21). This patient, who developed recurrence of the Philadelphia chromosome in the marrow, was retransplanted using the same conditioning regimen. She is alive, disease-free 777+ days after the first transplant and 185+ days after the second transplant. The remaining 13 patients transplanted for CML in the accelerated or blastic phase to date remain in complete remission with a normal bone marrow and peripheral blood status, absence of the Philadelphia chromosome, and presence of lymphohematopoietic cells of exclusively donor type. A Kaplan-Meier product limit estimate for the probability of being in remission is shown in Fig 1.

**Engraftment and marrow function.** One patient who died on day 2 from cardiac failure (UPN 38) could not be evaluated for engraftment. One other patient (UPN 71) died on day 2 from cardiac failure (UPN 38) could not be evaluated for engraftment. The patients maintained a WBC that exceeded 1.0 x 10^9/L or a platelet count of 40 x 10^9/L.

### Table 1. Cytogenetic Analysis of Cells in Peripheral Blood

<table>
<thead>
<tr>
<th>Time</th>
<th>No. of Samples</th>
<th>No. of Patients</th>
<th>Median Day</th>
<th>No. of Donor Cells</th>
<th>Total Cells</th>
<th>Donor Cells (%)</th>
<th>SE</th>
<th>Value</th>
<th>Relative Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-20</td>
<td>26</td>
<td>22</td>
<td>17</td>
<td>438</td>
<td>513</td>
<td>85.4</td>
<td>1.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21-40</td>
<td>32</td>
<td>24</td>
<td>29</td>
<td>403</td>
<td>514</td>
<td>78.4</td>
<td>1.81</td>
<td></td>
<td></td>
</tr>
<tr>
<td>41-70</td>
<td>35</td>
<td>23</td>
<td>60</td>
<td>537</td>
<td>634</td>
<td>84.7</td>
<td>1.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>71-100</td>
<td>36</td>
<td>25</td>
<td>84</td>
<td>707</td>
<td>777</td>
<td>91.0</td>
<td>1.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>101-160</td>
<td>25</td>
<td>21</td>
<td>130</td>
<td>620</td>
<td>665</td>
<td>93.2</td>
<td>0.97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>161-220</td>
<td>18</td>
<td>15</td>
<td>184</td>
<td>395</td>
<td>404</td>
<td>97.8</td>
<td>0.73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>221-365</td>
<td>29</td>
<td>18</td>
<td>284</td>
<td>608</td>
<td>613</td>
<td>99.2</td>
<td>0.36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;365</td>
<td>25</td>
<td>9</td>
<td>593</td>
<td>491</td>
<td>491</td>
<td>100.0</td>
<td>0.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2. Clinical Parameters Associated With Survival (Cox-Hazards)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>P Value</th>
<th>SE</th>
<th>Relative Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractoriness</td>
<td>1.79</td>
<td>0.69</td>
<td>5.98</td>
</tr>
<tr>
<td>Interstitial pneumonia</td>
<td>1.28</td>
<td>0.319</td>
<td>3.60</td>
</tr>
<tr>
<td>Acute GVHD (≥ grade 2)</td>
<td>2.61</td>
<td>0.872</td>
<td>13.59</td>
</tr>
<tr>
<td>Hemorrhagic cystitis</td>
<td>2.584</td>
<td>0.68</td>
<td>13.316</td>
</tr>
</tbody>
</table>

![Fig 1](image-url)
The median number of cells per patient examined was 115.5. The median number of cells per sample was 20 (range 1 to 50). The mode was 32. The median day of these examinations was 87.5 (range 12 to 767). The interquartile range was 117.5. Four thousand one hundred ninety-nine (4,199) of the cells examined were classified as donor cells (91.06% with an SE of 0.42%).

During the first 20 days, 85.4% of the cells were classified as donor. With time, the number of donor cells increased steadily until by day 365 after transplant only donor cells could be identified in the peripheral blood. A breakdown of the quantitative analysis over time is given in Table 1.

**Support during the first 30 days after transplantation.** Due to the brief period of aplasia, relatively few blood products were required to maintain a hemoglobin of ≥10 g/dL and a platelet count of ≥20 x 10^9/L. Patients transplanted in the high-risk group were given a median of 5 U RBCs (range 0 through 42) and five transfusions of single donor platelets (range 0 through 137). The patients transplanted in the standard-risk group received a median of 3 U RBCs (range 0 through 10) and a median of four transfusions of platelets (range 0 through 20). Eleven high-risk and eight standard-risk patients (38%) did not develop a temperature >100.5°F in the first 30 days and required no therapeutic antibiotics. Only one patient was given amphotericin-B for a fungal infection (UPN 71). One patient was documented to have bacteremia with *Pseudomonas aeruginosa* (UPN 43), probably derived from a cutaneous *Pseudomonas* abscess that antedated the transplant procedure. This patient responded promptly to appropriate antibiotic therapy. Two patients developed stomatitis with herpes simplex virus, which responded to Acyclovir. Three patients developed *Candida* esophagitis documented by endoscopy. All three responded promptly to oral nonabsorbable antifungal agents. Patients were discharged from the hospital when their granulocyte count was >0.5 x 10^9/L on three successive days and platelet and RBC counts were self-sustaining. The median day of discharge of all patients was 22 days (range 18 to 71), of the patients in the standard-risk group it was 21 days (range 18 to 33), and of the patients in the high-risk group it was 26 days (range 19 to 71).

**GVHD.** Acute GVHD was present in 15 patients. Of these fifteen patients, eleven showed grade 1 disease, one showed grade 2 disease, two showed grade 3 disease, and one showed grade 4 disease. All three patients with severe GVHD (grades 3 and 4) died in part from the GVHD. Chronic GVHD of grade 1 occurred in 5 patients, chronic GVHD of grade 2 occurred in 15 patients, and chronic GVHD of grade 3 occurred in 5 patients. Chronic GVHD resolved with no sequelae in all but two patients. Chronic GVHD was associated with death in 2 patients with grade 3 disease. Chronic GVHD has been completely absent to date in 16 of the 35 surviving patients. Of the 45 patients surviving 100 days, 19 or 42% have shown clinically significant chronic GVHD of grade 2 or greater at any time during their transplant.

**Interstitial pneumonia and hemorrhagic gastroenteritis.** Interstitial pneumonia occurred in six patients, four of whom died with the disease. In 2 patients cytomegalovirus could be identified by bronchoalveolar lavage, 2 patients had idiopathic interstitial pneumonia, and 1 patient each had pneumonia associated with *Legionella* and *Pneumocystis carinii*. Two patients developed hemorrhagic gastroenteritis. In one of the two patients, hemorrhagic gastroenteritis was associated with severe GVHD, of which the patient died. The other patient recovered.

**Late infections.** Late infections (past day 50) occurred in 13 patients. Two patients developed systemic fungal infections (*Candida albicans*, UPN 24; *Aspergillus fumigatus*, UPN 19), and 12 patients developed bacterial infections, all with gram-positive organisms. Of these 12 bacterial infections, 8 were caused by *Streptococcus pneumoniae*, and 4 by *Staphylococcus epidermidis*. All bacterial infections presented with fever and minimal associated clinical symptoms and had documented bacteremia. Most bacterial infections (11 of 12) occurred after day 120 and have not been seen after IV immunoglobulin therapy was extended to 1 year posttransplant.

**Survival.** Of the 50 patients transplanted, 35 remain alive in unmaintained clinical remission. The actuarial 3-year survival rate of this patient population is 65%. The survival curves for all patients transplanted are shown in Figs 2 and 3. All patients in the standard-risk group transplanted for either ANLL or CML are disease-free survivors, and only 1 of the 20 patients transplanted in the standard-risk group (for ALL, UPN 19) has died. This death was associated with chronic GVHD and systemic Aspergillus infection, the patient being in complete remission at the time of death.

Of the 30 patients transplanted in the high-risk group, 16 are alive at present in unmaintained clinical remission. Nine of the 14 patients transplanted for CML in accelerated or blastic phase are alive, and 7 of the 16 patients transplanted for advanced acute leukemia are alive in unmaintained complete remission. The survival curves for these patient groups are shown in Figs 4 and 5.

**Parameters affecting survival.** Parameters that might
affect survival were entered into a Cox regression proportional hazards model for death as outcome variable. The parameters included: diagnosis; disease status; risk group; age and sex of the recipient; time of return of blood counts; day of discharge; number of late infections; and the complications of hemorrhagic cystitis, hemorrhagic gastroenteritis, interstitial pneumonia, acute GVHD, and chronic GVHD. Refractory disease, interstitial pneumonia, hemorrhagic cystitis, and acute GVHD of grade 2 or greater were all significantly associated with death. These data are shown in Table 2.

DISCUSSION

Busulfan and Cy are an attractive combination for pretransplant conditioning. Preclinical studies in a rat model have demonstrated the importance of myelosuppression in combination with immunosuppression for preparing marrow graft recipients. In this model, the addition of busulfan, a nonimmunosuppressive but highly myelotoxic agent, to Cy, a moderately myelotoxic but highly immunosuppressive agent, permitted the reduction of Cy without compromising engraftment. Previous clinical trials using a combination of busulfan and high-dose Cy demonstrated excellent antileukemic efficacy, but serious toxicity similar to TBI-containing regimens. The present study attempted to show that the reduction of Cy would not compromise antileukemic effectiveness of the combination, but would markedly reduce the complication rate. The reduction of Cy to 120 mg/kg, the commonly used dose in TBI-containing regimens, permitted furthermore the direct comparison of busulfan to TBI in the hope of achieving overall a lower complication rate.

The data presented in this report bear out these predictions. The preparative therapy was well tolerated, and apart from moderate yet transient nausea and vomiting associated with Cy, no immediate toxicity occurred. Apart from one patient who died too early for evaluation, all patients, including those with refractory leukemia or in blastic phase of CML, achieved complete remissions and complete sustained engraftment. As predicted from the animal model, marrow recovery occurred rapidly. Fully functioning hematopoietic grafts were usually achieved within the first 2 weeks after transplantation. It is tempting to speculate that the busulfan, by virtue of its “space making” properties, was responsible for this short aplasia. It is equally possible, on the one hand, that the avoidance of TBI was less damaging to the microenvironment, permitting earlier engraftment. On the other hand, substituting cyclosporine and methylprednisolone for methotrexate in the prevention of GVHD might have reduced the induced aplasia after transplantation. This short period of aplasia resulted in a markedly reduced need for blood product support and, most important, in a surprisingly low incidence of infectious complications. There was a virtual absence of bacteremia (one patient) and only one patient required amphotericin-B administration. Other common complications, such as acute GVHD were also infrequent. The low incidence of severe acute GVHD may have resulted from prophylaxis with a new combination regimen of cyclosporine/methylprednisolone. The low incidence of early infectious complications resulting from short aplasia, lesser amounts of tissue toxicity, and ultraclean environmental conditions may have led to a reduced incidence of
GVHD, a postulate supported by a number of preclinical and clinical observations.\textsuperscript{15,18}

It is unclear to what extent the reduced incidence of interstitial pneumonia can be credited to the preparative regimen. Because radiotherapy and acute GVHD contribute to the development of interstitial pneumonia,\textsuperscript{19} the low incidence in our study is probably not just a spurious observation. Furthermore, the patients received IV immunoglobulin preparations and blood products derived from cytomegalovirus-antibody–negative donors, both procedures reportedly associated with a lower incidence of viral interstitial pneumonia.\textsuperscript{20,22}

Late complications seen after allogeneic bone marrow transplantation were not altered in frequency when compared with TBI-containing regimens. Some patients developed gram-positive bacteremias after 100 days, none of which led to the death of the patients. These often quite insidious infections have not been observed since the administration of IV immunoglobulin was extended to 1 year posttransplant.

Similarly, chronic GVHD occurred frequently. Fortunately, this complication has been very mild and in most patients chronic GVHD has resolved completely without sequelae.

The antileukemic efficacy of this regimen is apparent. Although the disease-free survival in regular-risk patients so far is outstanding, clearly additional follow-up time is required to ascertain that these patients are indeed cured. The excellent results achieved in advanced disease demonstrate a potent antileukemic effect, however. The results in accelerated and blastic phase of CML compare favorably to the development of interstitial pneumonia.\textsuperscript{7,8}

The patients studied here were at high risk for several reasons. They were older than patients in most comparable studies, some of our patients being 50 years old. Older age clearly increases the transplant risk.\textsuperscript{3,8,22} Many had advanced disease, including high-risk factors such as pretransplant hepatic dysfunction, cytogenetic abnormalities, CNS disease, and cutaneous involvement, all parameters associated with poor prognosis.

The results of this study are encouraging. This regimen may be more effective and less toxic than TBI-containing regimens for patients generally considered to be good transplant candidates, eg, those with acute leukemia in remission and CML in chronic phase. In addition, this regimen offers promise in circumstances such as CML in accelerated or blastic phase and in refractory acute leukemia in which transplantation results have been so poor that valid questions as to the appropriateness of allogeneic marrow transplantation have been raised. Furthermore, the low toxicity of this regimen might permit the use of additional antileukemic agents in patients with advanced disease.

This report suggests that this new regimen provides an alternative to traditional conditioning regimens that include TBI. It offers substantial promise in decreasing the morbidity and improving the outcome of patients undergoing allogeneic marrow transplantation.

**ACKNOWLEDGMENT**

We thank the nursing staff of the Bone Marrow Transplant Unit and the Ohio State University Housestaff for their outstanding efforts. We are indebted to all referring physicians; to Dr Leona Ayers, head of Microbiology; to Phyllis Kaldor, head nurse of the Bone Marrow Transplant Unit; to Linda K. Graff, Transplantation Coordinator; to Becky Gibbins, Clinical Protocol Nurse; and Judy Bishop, Data Coordinator, for their many contributions. We thank Judy French and Barbara Fowls for preparing the manuscript and for numerous other contributions.

**REFERENCES**

15. Tutschka PJ, Santos GW: Bone marrow transplantation in...
1388

TUTSCHKA, COPELAN, AND KLEIN

the busulfan treated rat. I. Effect of cyclophosphamide and rabbit anti-rat thymocyte serum as immunosuppression. Transplantation 20:101, 1975


Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen

PJ Tutschka, EA Copelan and JP Klein